Drugs / Sodium Zirconium Cyclosilicate (SZC)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05056727 | Sep 2021 → Feb 2024 | chronic kidney disease | AstraZeneca | Terminated | Missed primary Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium Zirconium Cyclosilicate (SZC) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05056727 ↗ |
| Route | Oral | “Powder for oral suspension” NCT05056727 ↗ |